Literature DB >> 14511307

An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage.

T Biss1, L Crossman, I Neilly, J Hanley.   

Abstract

We report a 71-year-old man who presented with severe subcutaneous and later psoas muscle haemorrhage in the presence of a raised white cell count and hepatosplenomegaly. A circulating factor VIII (FVIII) inhibitor was detected and bone marrow morphology confirmed the presence of a myeloproliferative/myelodysplastic disorder. Initial treatment with high dose FVIII followed by recombinant factor VIIa was unsuccessful. Haemorrhage was controlled by the administration of activated prothrombin complex concentrate (FEIBA; Baxter healthcare, CA, USA) in combination with prednisolone, cyclophosphamide and i.v. immunoglobulin. The inhibitor became undetectable 14 weeks after presentation. The white cell count responded initially to hydroxyurea and later to cyclophosphamide. There have been only two previous reports of acquired haemophilia A in association with myelodysplastic disorders and no previous report of an association with a myeloproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511307     DOI: 10.1046/j.1365-2516.2003.00806.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

1.  A rare case of acquired hemophilia A associated with myelodysplastic syndrome.

Authors:  Mihir Raval; Rekha Kallamadi; Dinesh Bande
Journal:  Int J Clin Exp Med       Date:  2012-06-15

2.  Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies.

Authors:  José María Bastida; María Teresa Cano-Mozo; Felix Lopez-Cadenas; Victor Eduardo Vallejo; Soraya Merchán; Cecilia Santos-Montón; David González-Calle; Javier Carrillo; Ana Africa Martín; Jose Angel Torres-Hernández; Marcos González; Francisco Martín-Herrero; Pedro Pabón; Jose Ramon González-Porras
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.